Cipla v Novartis: import qualifies as working of patent

The Indian pharmaceutical industry is a major manufacturer of cost-effective generic drugs and is set to become the leading exporter of generic pharmaceutical products. However, recently the Indian pharmaceutical industry has seen several landmark judgments which will have a far-reaching effect on Indian pharma players, as well as international pharma giants.

Read article >>

Subscribe to Our Blog

Get notification related to our new post

Name *

Email *

Leave a Reply

Your email address will not be published. Required fields are marked *